Roche Wins Priority FDA Review for Lung Cancer Drug

  • FDA to reach decision on alectinib before March 4, 2016
  • Drug may get nod for patients who resist standard chemotherapy

Roche Holding AG’s experimental drug alectinib will be fast-tracked by U.S. regulators to treat a form of aggressive lung cancer that has spread.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.